Background In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended...
C. Rudin, M.-J. Ahn, M. Schuler et al.· Annals of Oncology· 0 citations
The number of patients with solid tumours requiring intensive care is increasing as cancer survival improves and oncological treatments become more complex. Intensive care unit (ICU) admission decisions should not be based on cancer diagnosis, metastatic status or palliative treatment intent alone. This narrative revie...
Alicia Castelo-Loureiro, Amanda Lesmes González de Aledo, Mateo Bover-Larroya et al.· Cancers· 0 citations
Immune checkpoint inhibitors (ICI), alone or in combination with chemotherapy, are the standard first-line treatment for advanced non–small cell lung cancer (NSCLC) without actionable oncogenic drivers. Programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are routinely used biomarkers, yet...
J. Ramos-Paradas, N. Carrizo, Eva Álvarez et al.· Frontiers in Immunology· 0 citations
The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
Abstract Background Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization. Methods We performed compartment-specifi...
C. Fernández-Luna, J. Baena, A. Calles et al.· Journal for ImmunoTherapy of...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.